Who are ATB-346 mid-dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Celebrex, Cytotec, Celecoxib (Celebrex), NSAI treatment, VIMOVO 500/20, Metamizole and Ibuprofen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atb-346-mid-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ATB-346 mid-dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ATB-346 mid-dose (ATB-346 mid-dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Pain.

phase 2 NSAID COX-2 Pain Small molecule Live · refreshed every 30 min

Target snapshot

ATB-346 mid-dose (ATB-346 mid-dose) — Antibe Therapeutics Inc.. ATB-346 mid-dose is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ATB-346 mid-dose TARGET	ATB-346 mid-dose	Antibe Therapeutics Inc.	phase 2	NSAID	COX-2
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Celecoxib (Celebrex)	Celecoxib (Celebrex)	National Eye Institute (NEI)	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
NSAI treatment	NSAI treatment	London School of Hygiene and Tropical Medicine	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and/or COX-2)
VIMOVO 500/20	VIMOVO 500/20	Amgen	marketed	NSAID with proton pump inhibitor combination	COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole)
Metamizole and Ibuprofen	Metamizole and Ibuprofen	University Hospital, Basel, Switzerland	marketed	Nonsteroidal anti-inflammatory drug (NSAID) combination	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-05-27 — Celebrex · 10722456 · Formulation · US
2036-05-27 — Celebrex · 10799517 · Formulation · US
2036-05-27 — Celebrex · 9949990 · Formulation · US
2036-05-27 — Celebrex · 9795620 · Formulation · US
2036-05-27 — Celebrex · 9572819 · Formulation · US
2036-05-27 — Celebrex · 10376527 · Formulation · US

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ATB-346 mid-dose — Competitive Intelligence Brief. https://druglandscape.com/ci/atb-346-mid-dose. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing